deferasirox + placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-transfusion Dependent Thalassemia
Conditions
Non-transfusion Dependent Thalassemia
Trial Timeline
Nov 1, 2008 → Jun 1, 2012
NCT ID
NCT00873041About deferasirox + placebo
deferasirox + placebo is a phase 2 stage product being developed by Novartis for Non-transfusion Dependent Thalassemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00873041. Target conditions include Non-transfusion Dependent Thalassemia.
What happened to similar drugs?
1 of 2 similar drugs in Non-transfusion Dependent Thalassemia were approved
Approved (1) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00940602 | Phase 2 | Completed |
| NCT00873041 | Phase 2 | Completed |
Competing Products
5 competing products in Non-transfusion Dependent Thalassemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| deferasirox | Novartis | Approved | 43 |
| REGN7999 + Placebo | Regeneron Pharmaceuticals | Phase 2 | 42 |
| Placebo Matching Mitapivat + Mitapivat | Agios Pharmaceuticals | Phase 3 | 38 |
| SLN124 + Placebo | Silence Therapeutics | Phase 1 | 19 |
| SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as Placebo | Silence Therapeutics | Phase 1 | 11 |